ENTA soared on expectations for the COVID program, but lately investors have (unduly, IMO) downgraded everything related to COVID as though the virus will just disappear.
Meanwhile, ENTA’s RSV program has taken longer than originally anticipated to develop, due to a low incidence of RSV infections during the pandemic, which has slowed patient enrollment in ENTA’s RSV trials.
What DD and other fail to recognize is repeated years of failures in the clinic with HBV and NASH programs. Investors have apparently lost all trust. The attempt to market these dead programs as for partnership is a complete joke!
News 
Market Data 
Discover 
